For subscribers
Singapore well placed for investments in new drugs, says pharma giant MSD
Sign up now: Get ST's newsletters delivered to your inbox
Singapore is set to receive its due share of the deluge of investments flowing into the research and development of new drugs, including mRNA-based vaccines and therapies.
While mRNA vaccines have earned validation through coronavirus jabs, the future of the breakthrough technology they represent goes beyond Covid-19 itself, said Singapore-based David Peacock, who was appointed last month as the Asia-Pacific president of MSD, the international trade name of American pharmaceutical giant Merck & Co.
